Top Markets
Coin of the day
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Κατάταξη σε μετοχές #29513
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Τιμή μετοχής
$0.12952814
Κεφαλαιοποίηση
$21.11M
Αλλαγή (1 ημέρα)
4.40%
Αλλαγή (1 έτος)
-35.74%
Χώρα
FR
Εμπόριο GenSight Biologics S.A. (SIGHT)

Κατηγορία

Ιστορικό τιμής μετοχής για την GenSight Biologics S.A. (SIGHT)
Υψηλότερη τιμή κλεισίματος: $0.11 στις 2026-08-01

Χαμηλότερη τιμή κλεισίματος: $8.93 στις 2016-07-01
Ιστορικό τιμής μετοχής της GenSight Biologics S.A. από 2016 έως 2026
Ετήσια απόδοση τιμής μετοχής
Έτος Απόδοση
2026 (TTM) 0.84%
2025 -61.96%
2024 -40.41%
2023 -85.79%
2022 -40.62%
2021 -23.84%
2020 252.34%
2019 -43.91%
2018 -36.71%
2017 -20.44%
2016 0.00%
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Τιμή μετοχής Μεταβολή 1Έτ% Χώρα
$544.11 39.24%
US
$1.02K 56.01%
NL
$144.46 417.59%
US
$117.42 -19.34%
AU
$753.80 8.66%
CH